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Abstract
Surveillance of highly pathogenic viruses circulating in both human and animal populations
is crucial to unveil endemic infections and potential zoonotic reservoirs. Monitoring the bur-
den of disease by serological assay could be used as an early warning system for imminent
outbreaks as an increased seroprevalance often precedes larger outbreaks. However, the
multitude of highly pathogenic viruses necessitates the need to identify specific antibodies
against several targets from both humans as well as from potential reservoir animals such
as bats. In order to address this, we have developed a broadly reactive multiplex micro-
sphere immunoassay (MMIA) for the detection of antibodies against several highly patho-
genic viruses from both humans and animals. To this aim, nucleoproteins (NP) of Ebola
virus (EBOV), Marburg virus (MARV) and nucleocapsid proteins (NP) of Crimean-Congo
haemorrhagic fever virus, Rift Valley fever virus and Dobrava-Belgrade hantavirus were
employed in a 5-plex assay for IgG detection. After optimisation, specific binding to each
respective NP was shown by testing sera from humans and non-human primates with
known infection status. The usefulness of our assay for serosurveillance was shown by
determining the immune response against the NP antigens in a panel of 129 human serum
samples collected in Guinea between 2011 and 2012 in comparison to a panel of 88 sera
from the German blood bank. We found good agreement between our MMIA and commer-
cial or in-house reference methods by ELISA or IIFT with statistically significant higher
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binding to both EBOV NP and MARV NP coupled microspheres in the Guinea panel. Finally,
the MMIA was successfully adapted to detect antibodies from bats that had been inoculated
with EBOV- and MARV- virus-like particles, highlighting the versatility of this technique and
potentially enabling the monitoring of wildlife as well as human populations with this assay.
We were thus able to develop and validate a sensitive and broadly reactive high-throughput
serological assay which could be used as a screening tool to detect antibodies against sev-
eral highly pathogenic viruses.
Author summary
Zoonotic pathogens, which are transmitted from their animal, arthropod or insect host to
humans, have been responsible for some of the most devastating disease outbreaks in
human history, including the largest Ebola virus disease outbreak in West Africa in 2014–
2016, which resulted in over 28,000 infected persons and caused 11,310 deaths. Changes
in land use practices, the climate and overall globalization concurrently brings human
populations into closer contact with animals, arthropods, insects and the zoonotic patho-
gens they host, whilst increasing the possibility for local outbreaks to expand and spread
internationally. Here we developed a multiplex serological assay that can be used to
simultaneously detect IgG antibodies to 5 highly pathogenic zoonotic viruses, Ebola -,
Marburg -, Crimean Congo haemorrhagic fever—, Dobrava-Belgrade- and Rift Valley
fever virus. Our assay was designed to be able to detect antibodies to multiple species of
viruses within each family, and was adapted to detect animal (specifically bat) as well as
human antibodies. This assay could be used as a serological surveillance tool to monitor
evidence of infection with several highly pathogenic viruses in human and wildlife popu-
lations, which is important for risk assessment and prevention of zoonotic human infec-
tious disease outbreaks.
Introduction
Multiple genera and species of viruses within the Filoviridae, Nairoviridae, Hantaviridae and
Phenuiviridae families are highly pathogenic to humans, and members of these virus families
have also been documented on the African continent. Several strains of Ebolavirus and Mar-
burgvirus within the Filoviridae family have been known to cause sporadic disease outbreaks
in multiple African countries, including the largest Ebola virus (EBOV) epidemic in West
Africa in 2014–2016 which resulted in over 28,000 infected individuals and caused 11,310
deaths [1–3]. Indeed, the current EBOV outbreak in the Democratic Republic of the Congo
(3,453 confirmed and probable Ebola virus disease cases and 2264 confirmed and probable
Ebola virus deaths as of 24.03.2020 [4]) corroborates the on-going threat posed by ebolaviruses
and highlights the need for continuous surveillance in endemic countries, as outbreaks can be
extremely difficult to control. The tick-borne Crimean-Congo haemorrhagic fever virus
(CCHFV), a member of the Nairoviridae family, has been responsible for the most cases of
human morbidity and mortality, and has been detected in multiple African countries, fre-
quently causing nosocomial infections / outbreaks [5–7]. The mosquito-transmitted Rift Val-
ley fever virus (RVFV), which belongs to the Phenuiviridae family, has also been responsible
for several large outbreaks of disease in Africa, resulting in thousands of human infections and
deaths, in addition to economically devastating livestock losses [8–10]. Disease outbreaks of
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RVFV correlate strongly with environmental factors such as heavy rainfall and flooding [11].
Viruses within the Hantaviridae family have only recently begun to be documented in Africa,
including Sangassou virus, Tanganya virus and Magboi virus, although it is speculated that
there might be more as-yet-undocumented African hantaviruses [12–16].
All virus species included in this study are zoonotic, and reservoirs have been identified for
all species except for ebolaviruses for which bats are the presumptive reservoir hosts [17,18].
For some of these viruses sentinel species can provide advanced warning that nearby human
populations could be at risk [19–21]. Abortion storms in sheep and goats can indicate that
RVFV is circulating in these animals, and unusual numbers of deceased non-human primates
(NHPs) (e.g. gorillas and chimpanzees) could be a result of ebolavirus epizootics [22,23].
Transmission of these highly pathogenic viruses to humans occurs through contact with
infected body fluids or excretions of their reservoir hosts, and in the case of RVFV and
CCHFV also through the bite of their infected arthropod vectors (mosquitoes and ticks respec-
tively). EBOV, MARV, and CCHFV can also be transmitted from human to human by contact
with blood and other body fluids, potentially expanding exposed individual cases into epi-
demic outbreaks that have the potential to spread globally.
Early detection and diagnosis is paramount to preventing the transmission and spread of
highly pathogenic viruses within human populations. Knowledge of their circulation in spe-
cific regions and/ or populations can ensure their inclusion in differential diagnosis of
unknown disease aetiologies where appropriate. Active serological surveillance in animal pop-
ulations can help to anticipate spill overs to humans, as well as aiding in the search for virus
reservoirs [24,25]. Regular serological screening of livestock as sentinels for these viruses (pri-
marily for CCHFV and RVFV) can help protect humans with whom they have regular contact
from zoonotic infection, and aid in maintaining livestock health (in the case of RVFV). Most
laboratory tests for serological surveillance are performed in a single test format using conven-
tional plate-bound enzyme linked immunosorbent assay (ELISA) techniques. It is often desir-
able, however, to monitor the serostatus against different viral diseases simultaneously in
order to reduce materials used, as well as cost and effort. Among the multiplex platforms
described the suspension array technology, also called Luminex xMAP technology (Luminex
Corp., Austin, USA), is of interest for broad-range use in standard laboratories, as it is com-
mercially available and technically open to different applications [26]. The suspension array
technology uses magnetic polystyrene microspheres with a diameter of 6.5 μm which are
embedded with precise ratios of red and infrared fluorescent dyes, thus yielding an array of
100 bead sets which are spectrally unique and can be distinguished by flow cytometry. In a
serological assay, the assay principle is similar to an indirect ELISA: First, differently coloured
microspheres are covalently coupled to immunodominant antigens of different viruses (e.g.,
either purified recombinant proteins or cell lysates of virally infected cells); individual serum
samples are then incubated with a mixture of microbeads coupled to different immunodomi-
nant antigens and positive signals are detected using biotinylated anti-species antibodies fol-
lowed by the fluorescent reporter streptavidin-phycoerythrin. The Luminex flow cytometer
addresses (i) the fluorescent signature of the microsphere set and (ii) the intensity of the
reporter signal per microsphere set. Thus, antibodies against multiple viruses can be detected
simultaneously from a minimal sample volume of 1–2 μL serum.
Here, we describe the development of a broadly reactive multiplex microsphere immunoas-
say (MMIA) for the detection of antibodies in human and animal serum samples as generated
in response to infection by members of the Filoviridae, Phenuiviridae, Nairoviridae and Hanta-
viridae families.
The nucleoprotein (NP) of EBOV and MARV and the nucleocapsid proteins (NP) of
CCHFV, Dobrava-Belgrade virus (DOBV) and RVFV were chosen to function as the target
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antigens in our MMIA as NPs have previously been shown to possess high immunogenicity, in
addition to their sequences being conserved across different virus species of one genus [27–
35]. Therefore, by using these proteins each antigen in the MMIA is designed to be broadly
reactive, and should be able to detect antibodies to multiple virus species within each family
(with the possible exception of the new-world hantaviruses).
Following assay optimisation utilizing hyperimmune animal serum for individual viruses,
the MMIA was tested for specificity and validated with the serum of laboratory-infected NHPs
(for EBOV, MARV and RVFV) and previously characterized human serum (for CCHFV and
DOBV). Following validation, the MMIA was used to screen 129 human serum samples col-
lected from Guinea in 2011 and 2012. Furthermore, a pan-species antibody detection system
was established in order to broaden the scope of the newly established assay so as to enable ver-
satile serosurveillance. This was achieved by substituting the secondary antibody with a mixture
of biotinylated protein A and protein G. The assay was then validated for its ability to detect
antibodies from other animal species using the serum of insectivorous micro bats caught in the
Ivory Coast and then immunized with EBOV- and MARV- virus-like particles (VLPs). Here,
we present the development of a high-throughput screening tool that can be used to assess the
presence and prevalence of IgG antibodies against 5 different highly pathogenic viruses in
human and animal populations. Our MMIA was used to successfully detect antibodies against
these viruses in a cohort of human serum samples from Guinea, the German blood bank and
wild bats from the Ivory Coast, proving its versatility as a broadly reactive surveillance tool.
Materials and methods
Ethics statement: animal and human sera
Hyperimmune sera against EBOV NP, MARV NP, RVFV NP and CCHFV NP. In
order to establish the assay by optimising the coupling of NPs to microspheres and assessing
cross reactivity between antigens, hyper immune mouse serum was generated against EBOV
NP (Zaire ebolavirus, isolate Ebola virus/H.sapiens-tc/COD/1976/Yambuku-Mayinga),
MARV NP (Lake Victoria marburgvirus—Angola2005, strain "Ang0998") and RVFV NP (iso-
late "688/78") using the recombinant proteins. All animal experiments with mice using bacteri-
ally expressed EBOV NP, MARV NP, and RVFV NP were registered and approved by the
responsible governmental authorities (Office for Health and Social Affairs Berlin, LAGeSo;
registration number H0129/19). Animals were housed according to national regulations. The
physical condition of the animals was monitored daily. No animal became ill prior to the
experimental endpoint. Hyperimmune sera were generated through serial inoculation of mice
with the purified recombinant NPs of RVFV, EBOV and MARV according to standard proce-
dures [26]. Hyperimmune sheep serum containing anti-CCHFV NP antibodies was generated
by AltaBiosciences Ltd. (United Kingdom) using 1 mg purified CCHFV NP (highly similar to
strain Baghdad 12) in a 1-ml volume [36,37].
Human and non-human primate serum samples. Human serum samples that had previ-
ously tested serologically positive for DOBV were kindly provided by J. Hofmann from the
Institute of Virology, Charité –Universitätsmedizin Berlin, Berlin, Germany. The 129 human
serum samples collected from febrile patients in Guinea in 2011 and 2012 were collected in
accordance with (ethics statement 09/CNERS/12). Anonymised human serum samples from
the German blood bank (n = 88), the Robert Koch Institute (n = 3) and the Laboratoire
National d’Appui au Développement Agricole (n = 2) were used to optimise the MMIA and as
a presumptive “negative control” population in order to establish background readings for the
MMIA as well as the recombinant NP based EBOV and MARV in-house ELISAs. All human
sera were heat inactivated at 56˚C for at least 30 minutes, prior to any serological analysis.
PLOS NEGLECTED TROPICAL DISEASES Multiplex immunoassay development to detect antibodies against highly pathogenic viruses
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008699 October 23, 2020 4 / 23
In order to validate the MMIA for anti CCHFV IgG antibody detection, human serum sam-
ples (10) were obtained from the WHO Collaborating Centre for Virus Research & Reference
(Special Pathogens)–PHE Porton Down, UK. Original samples were collected from febrile
patients who contracted disease in (i) Tajikistan in 2015–2016, (ii) Nigeria in 2015 and
received a laboratory diagnosis of CCHFV. Sera samples were not collected specifically for this
work, thus ethical approval for the study design was not required. Samples were anonymised
within Tajikistan and Nigeria and investigators were supplied with sequentially numbered
samples. Samples received a confirmatory test at Public Health England, UK.
Serum samples from NHPs infected with RVFV (strain not specified), MARV or EBOV
were used as surrogate serum samples to validate the MMIA as known serologically positive
human samples for these viruses were not available. NHP sera have previously been shown to
be able to function as a substitute for human sera in serological assays [38]. NHP sera positive
for antibodies against RVFV (strain not specified), CCHFV (strain not specified) and EBOV
were kindly provided by Gary Kobinger of the National Microbiology Laboratory, Winnipeg,
Canada (animal protocol number H-08-015, title: Development of antiserum against for
Machupo, Junin, CCHFV, Hendra, Nipah, and Rift Valley Fever Virus in non-human primates
for human diagnostic purposes) to function as positive controls in the MMIA. Sera used for
validation of the MMIA were generated as part of various vaccine trials through the infection
of NHPs with EBOV-Mayinga [39], EBOV-Makona [40,41], Reston virus (RESTV Pennsylva-
nia 1989 and Philippines 2008) and MARV-Angola in the BSL-4 facility at the NIH Rocky
Mountain laboratories (RML), Montana, USA. Serum samples were taken at various time
points post-infection and used to validate the MMIA for reactivity to the corresponding NP
coupled microspheres. All NHP sera were inactivated on dry ice by gamma irradiation accord-
ing to IBC-approved standard operating procedures prior to any manipulation outside of a
BSL-4 laboratory.
Bat serum samples. Twenty Mops condylurus bats were captured with mist nets at a resi-
dence in Koffikro Village in Ivory Coast (geographic coordinates: N 05˚ 19.340´; W 003˚
49.431´). Subsequently, the bats were kept in captivity at LANADA Institute (Laboratoire
National d’Appui au Développement Agricole) Bingerville, Ivory Coast. Capture, animal work
and immunization was executed in accordance with ethics agreement by the respective gov-
ernmental authority (LANADA Institute, No. 05/virology/2016). The bats were pre-bled, fol-
lowed by first subcutaneous inoculation and boosted after 15 days with 100 μl VLPs-adjuvant
formulation into the loose skin on the neck. Appropriate amounts of EBOV-VLPs (#0550–
001, IBT Bioservices, 1.54 mg/ml) or MARV-VLPs (#0566–001, IBT Bioservices, 3.725 mg/ml)
were diluted in sterile PBS to a final concentration of 50 μg of VLPs (10 bats each for EBOV-
and MARV-VLPs) in 50 μl and mixed with 50 μl Alhydrogel adjuvant 2% (CAS No 21645-51-
2, InvivoGen). Serum was collected 24 days after first inoculation by cardiac puncture under
anaesthesia with Isoflurane (1214, cp-pharma) and frozen at -80˚C.
Recombinant nucleo/nucleocapsid proteins
The nucleo and nucleocapsid proteins (NPs) of EBOV, MARV, CCHFV, RVFV and DOBV
were chosen as the antigens in the MMIA, due to their high immunogenicity and because their
sequences are conserved across different virus species enabling the detection of antibodies
against multiple virus species within one family. To generate recombinant NPs full length NPs
of RVFV (GenBank accession DQ924959), EBOV (NP_066243), MARV (ABE27061), CCHFV
(unpublished NP sequence with three conserved amino-acid substitutions (T111I, R195H and
H445D) from the published Baghdad 12 strain (GenBank accession CAD61342.1)) and DOBV
(GenBank accession. AJ269550.1) were bacterially expressed as His-tagged fusion proteins and
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purified using Ni-NTA affinity chromatography. The plasmids encoding EBOV NP, MARV
NP and RVFV NP were synthesised, and the recombinant proteins were custom-made by
Genexpress (Berlin, Germany). Briefly, codon-optimized genes, for expression in E.coli, were
cloned into expression vector pQE100S. Expression was induced with 2 mM isopropyl β-D-
1-thiogalactopyrano-side overnight at room temperature, His-tagged proteins were isolated
under native (Protein X) conditions and purified using Profinity Ni-IMAC Resin column
(BioRad, California, US) according to standard procedures. The bacterial lysate used to coat
one microsphere region and to pre-incubate the serum samples was also supplied by GenEx-
press and was generated by transforming the empty expression vector pQE100S into E.coli.
The culture was grown after induction for 4 hours at 37˚C and the bacterial lysate was then
also isolated under native conditions. CCHFV NP and DOBV NP were expressed and purified
as previously described [42,43]. Protein gel electrophoresis followed by Coomassie staining
was utilized to assess the purity of each protein (S1 Fig). His-tagged or tag-free (CCHFV only,
where His-tag had been removed by cleavage and size exclusion chromatography) proteins
were subsequently coupled to paramagnetic Magplex microspheres.
Multiplex microsphere immunoassay
Protein coupling to microspheres. All proteins were dialysed into PBS and then coupled
covalently to different regions (regions 12, 14, 15, 18, 20, 21 and 25) of Magplex microspheres
(Luminex, Austin, Texas, USA) using the standard protocol as outlined in the xMAP Cook-
book (44). Briefly, 1 × 106 microspheres were washed in distilled water and subsequently resus-
pended in NaH2PO4 prior to activation by addition of Sulpho-NHS (24520, Thermo Fisher
Scientific) and EDC (22980, Thermo Fisher Scientific). Microspheres were then washed and
resuspended in 50 mM MES buffer pH 5.0 (or PBS pH 7.2 in the case of EBOV NP and MARV
NP) prior to the addition of varying amounts (5–70 μg) of either EBOV NP (region 20),
MARV NP (region 18), RVFV NP (region 15), CCHFV NP (region 12), and DOBV NP (region
14), as well as 50 μg bacterial lysate proteins (region 21) and buffer without any proteins
(region 25) that were used as negative controls. Bacterial lysate (derived from E.coli trans-
formed with an empty expression vector) coupled to microspheres, as well as activated, un-
coupled microspheres were included in every assay (every microsphere mix) to control for
antibodies binding non-specifically to bacterial proteins or the microspheres themselves. Pro-
teins were incubated with microspheres for 4 hours at room temperature with rotation, after
which protein-coupled microspheres were washed twice in PBS-TBN (PBS, 0.1% BSA, 0.1%
Tween-20 and 0.05% sodium azide) and then stored in PBS-TBN at 4˚C.
Assay optimisation and detection of human IgG antibodies. The MMIA assay was opti-
mised by varying the amount of each NP coupled to microspheres, the concentration of
serum, the assay buffer, and the percentage of E.coli lysate used in the assay buffer in the pre-
incubation step. The final optimised assay conditions and protocol are as follows: Serum sam-
ples were diluted 1:400 in optimised assay buffer (LowCross buffer (100 125, Candor) + 5% E.
coli lysate) and incubated for 30 minutes at room temperature prior to incubation with NP
coupled microspheres. Each diluted serum sample was then added in triplicate to a mix of 7
microsphere regions (5 microsphere regions bound to viral proteins plus 2 control regions),
containing 1,000 microspheres of each region. The serum-microsphere mix was then incu-
bated for 1 hour at room temperature with continuous shaking (700 rpm). The microspheres
were subsequently washed 3 times in wash buffer (0.1% Tween-20 in PBS pH 7.2) prior to
incubation for 30 minutes in biotin-conjugated goat anti-human IgG secondary antibody (Fc-
gamma specific, 109-065-088, Dianova (Jackson)), diluted 1:2,500 in LowCross buffer. Micro-
spheres were washed again 3 times in wash buffer and then incubated for 30 minutes in
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Streptavidin-R-Phycoerythrin (PJRS27, Prozyme) diluted 1:2,500 in LowCross buffer, with
continuous shaking. A final wash step (3 × in wash buffer) preceded the re-suspension of the
antibody-bound microsphere mix in PBS containing 1% BSA and analysis on a Bio-Plex 200
(Bio-Rad Laboratories, Munich, Germany). Care was taken to keep the fluorescent Magplex
microspheres protected from light at all times.
Detection of bat sera in pan-species MMIA. The MMIA was adapted to detect specific
antibodies targeting EBOV NP and MARV NP from bat serum samples by using a mixture of
biotinylated protein A and protein G (29989, Pierce Protein A, Biotinylated, and 29988, Pierce
Recombinant Protein G, Biotinylated Thermo Fisher Scientific). The MMIA was carried out as
described above, with the exception that biotinylated Protein A and Protein G were diluted to
a final concentration of 2 μg/mL each in assay buffer and used in place of the biotinylated anti-
human IgG secondary antibody, and a 1:200 dilution of bat serum was used instead of a 1:400
dilution, as this resulted in a higher signal to background ratio.
Confirmation assays
Further testing of serum samples was performed by re-testing selected serum samples (includ-
ing those that tested positive for respective viral antigens in the MMIA) using a commercially
available serological assay for each specific viral antigen, or an in-house ELISA. For CCHFV,
MMIA-positive sera were assayed by ELISA (D-5052 VectoCrimea-CHF-IgG, Vector-Best) for
anti-CCHFV NP IgG antibodies according to the manufacturer’s instructions. For RVFV and
DOBV, MMIA-positive sera were assayed for anti-RVFV (FI 280a-1005 G, EUROIMMUN) or
anti-DOBV (FI 278h-1010-1 G, EUROIMMUN) IgG antibodies by indirect immunofluores-
cence test (IIFT) according to the manufacturer’s instructions. The presence of IgG antibodies
targeting MARV NP and EBOV NP in human sera was confirmed by in-house ELISAs. Briefly,
the ELISA assay was developed using recombinant EBOV NP and MARV NP. 96-well plates
were coated overnight with 1 μg/mL (50 ng/well) MARV NP and 0.7 μg/ml (35 ng/well) EBOV
NP diluted in Carbonate buffer at 4˚C. After washing in wash buffer (0.1% Tween-20 in PBS
pH 7.2), blocking buffer (wash buffer containing 3% skim milk powder) was added to each
well and incubated for 1 hour at room temperature. After the removal of the blocking buffer,
serum samples diluted 1:400 in wash buffer containing 4% skim milk powder were added to
each well in triplicate. Following a 1 hour incubation step at room temperature, serum samples
were removed, and wells were washed 4 times in wash buffer prior to the addition of HRP con-
jugated goat anti-human secondary antibody (62–8420, Thermo Fisher Scientific). After 1
hour incubation, the secondary antibody was removed and cells were washed 8 times in wash
buffer. TMB solution (S-004-3-TMB, Seramun) was then added to each well, and after a 15
minute incubation at room temperature 0.25 M H2SO4 solution (319570-500ML, Sigma
Aldrich) was also added to each well and the plate was read in a Tecan Photometer analyser at
a wavelength of 450 nm (referenced to 620 nm).
Data processing and analysis
All data analysis was performed using R (version 3.5.1) [45] and GraphPad Prism (version
7.04). To this aim, median fluorescence intensity (MFI) readings from three technical repli-
cates per sample measured by a Bio-Plex 200 (Bio-Rad) instrument were imported to R using
the package XLconnect [46] and readxl [47]. Data processing was done using packages con-
tained in the tidyverse [48] while plots were generated using ggplot2 [49] and ggpubr [50]. To
determine the cutoff, the 99th percentile for MFI values in the German blood bank population
was determined for each antigen using the dlookr [51] package. Based on these cutoff values,
contingency tables for both the German blood bank panel and the Guinea serum panel were
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prepared and Fisher’s exact test was employed using GraphPad Prism to calculate whether or
not statistically significant differences in the seroprevalences, and at which odds ratios, existed
between the German and the Guinea sample panels.
Results
Optimisation of protein coupling and assay conditions
MMIA conditions were optimised using hyperimmune mouse and sheep sera and presumed
negative human sera, in order to obtain the highest median fluorescent intensity (MFI) signal
possible from specific antibodies present in serum samples, whilst maintaining the lowest pos-
sible background signal from non-specific interactions with antigen-coupled microspheres (S2
Fig). Assay optimisation should facilitate differentiation between positive and negative results
and increase confidence in true positive and true negative results. The signal intensity of the
MMIA was optimized by varying the amount of each NP bound to microspheres while serum
titration, the usage of a specific buffer (LowCross) and the addition of E.coli lysate in a pre-
incubation step was used to minimize non-specific background binding (S2 Fig). After optimi-
sation signal intensities were found to be highest when employing 20 μg DOBV NP, 20 μg
CCHFV NP, 35 μg RVFV NP, 20 μg MARV NP and 20 μg EBOV NP, respectively, per 1 × 106
microspheres during protein coupling. Optimal assay conditions were achieved when using a
1:400 dilution of human sera and when a 30 minute pre-incubation step in assay buffer con-
taining 5% E.coli lysate was included, in order to reduce/eliminate background MFI signals
arising from antibodies targeting bacterial proteins present in human or animal serum
(S2 Fig).
MMIA validation using sera from virus-infected non-human primates or
previously characterised human samples
The ability of the MMIA to detect IgG antibodies specific for RVFV NP, EBOV NP and
MARV NP, arising as a result of viral infection rather than protein inoculation, was verified
using sera from NHPs experimentally infected with RVFV, EBOV or MARV (Fig 1). Here,
testing of one sample from a NHP which had been experimentally infected with RVFV
resulted in very high MFI readings (27,750) from the RVFV-NP-coupled microspheres, and
MFI readings equivalent to background levels from the other viral NP-coupled microspheres,
hereby confirming the specificity of our assay for detection of past RVFV infections. Serum
samples from 3 NHPs infected with EBOV-Mayinga [39], 8 NHPs infected with EBOV-Ma-
kona [40,41] and 3 NHPs infected with RESTV taken at various time points post-infection (6,
14, 28, 35 or 42 days after infection) were compared in the MMIA with sera taken pre-infec-
tion (Fig 1). Here, the MMIA revealed an incremental increase in MFI readings of these sera
from the EBOV NP-coupled microspheres. While the pre-bleed sera and the sera taken 6 days
after infection showed MFI reading at background levels, MFI values increased to ~10,000 14
days after infection, then up to almost 30,000 42 days post infection. Simultaneously, signals
equivalent to background levels were detected in these serum samples from the other viral NP-
coupled microsphere regions, thus validating this assay for the quantitative detection of NP-
specific IgG antibodies from EBOV-infected NHPs (Fig 1). Additionally, high MFI readings
(~15,000) from RESTV infected NHP serum samples demonstrated the ability of the MMIA to
detect evidence of infection from a range of ebolavirus species. Sera taken from 2 NHPs
infected with MARV-Angola 42 days after infection resulted in high MFI readings in the
MMIA from MARV NP-coupled microspheres when compared to the pre-infected sera.
Serum from a third NHP taken 42 days after infection with MARV-Angola failed to show
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evidence of seroconversion in the MMIA, however, the confirmatory MARV-NP ELISA
showed congruent results indicating that the MMIA faithfully reflects the serostatus of the
infected animals (Table 1). The absence of a positive signal in the MMIA and ELISA is there-
fore most likely due to the absence of anti-MARV NP-specific IgG antibodies in the serum
Fig 1. Validation of the MMIA using serum samples from humans or NHPs known to be infected with RVFV (1 NHP), EBOV (14 NHPs), MARV (3 NHPs),
CCHFV (10 humans from Tajikistan or Nigeria), or DOBV (2 humans from Europe). Previously characterised serum samples were used as a validation panel to
confirm the ability of the MMIA to detect anti-NP antibodies generated in response to infection with these viruses. These serum samples were assayed by MMIA under
the same conditions that were used to assay the serum panels from the German blood bank and Guinea, thus providing a range of MFI values for each viral NP coupled
microsphere region for known positive serum samples. For EBOV and MARV validation, serum taken from each NHP prior to experimental infection (pre) is
compared to serum taken at various time points post-infection. For the RVFV NHP serum and for CCHFV and DOBV human serum, samples taken at a single time
point after infection are compared to presumed negative human serum samples.
https://doi.org/10.1371/journal.pntd.0008699.g001
Table 1. Comparison between the MMIA and the commercial IIFT/ELISA or in-house ELISA results using the
serum samples from the validation panels. � Only validation panels where all samples did not test 100% positive
were confirmed by commercial immunoassay. �� The same serum samples tested positive in both immunoassays.
Serostatus (number positive/number tested)
Samples Antigen MMIA IFFT/ELISA
CCHFV validation panel CCHFV 9/10�� 9/10��
RVFV 2/2 2/2
DOBV validation panel DOBV 2/2 N/D�
EBOV validation panel EBOV 17/33�� 17/33��
MARV validation panel MARV 2/6�� 2/6��
RVFV validation panel RVFV 1/1 N/D�
https://doi.org/10.1371/journal.pntd.0008699.t001
PLOS NEGLECTED TROPICAL DISEASES Multiplex immunoassay development to detect antibodies against highly pathogenic viruses
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008699 October 23, 2020 9 / 23
sample. Overall, these data validate the MMIA for the detection of anti-MARV NP-specific
IgG antibodies in NHP sera.
Next, a panel of 10 human serum samples that had previously been characterized for
CCHFV serologically and by RT-PCR were used to validate the MMIA for anti-CCHFV NP
antibody detection. All sera that had tested positive by CCHFV ELISA (Vector-Best, antigen
CCHFV NP) also tested positive in the MMIA with MFI readings ranging from 3000 to 30,000
from the CCHFV NP coupled microspheres, thus confirming the ability of the MMIA to detect
IgG antibodies generated during infection against CCHFV. Interestingly, 3 of these samples
from Nigeria also had high MFI values from the RVFV NP coupled microspheres (MFI 4606,
12,786 and 20,233), potentially corresponding to human sera double positive for an anti-
CCHFV and anti-RVFV NP titer.
Finally, the ability of the MMIA to detect anti-DOBV NP IgG antibodies in human sera was
assayed using human serum samples from patients that had previously tested PCR/ELISA pos-
itive for anti-DOBV IgG. These serum samples were also positive in the MMIA, with high MFI
readings (>20,000) detected from the DOBV NP coupled microspheres, and background level
signals detected for the other viral NP coupled microsphere regions.
Overall, high MFI values (ranging from 3000–30,000 MFI units) were obtained from sera of
known positive status for the corresponding viral NP-coupled microspheres, whilst the back-
ground MFI signal from the other 4 viral NP-coupled microspheres and the unbound micro-
spheres remained low/negative (ranging from ~ 30–1800 MFI units).
Establishment of a negative/positive threshold for each NP-coupled
microsphere region
In order to establish the negative/positive threshold for the MMIA, a panel of 88 human serum
samples from the German blood bank was tested in triplicate. This resulted in different average
MFI readings, and clustering pattern of MFI values, for each NP-bound microsphere region
(Fig 2). For each microsphere region, the negative/positive threshold was then assigned as the
99th percentile. This was based on the assumption that, with the exception of DOBV, none of
the analysed highly pathogenic viruses are endemic in Germany, which is why a population
based cut-off value was established. However, to allow for single sera with higher reactivity the
99th percentile was chosen to discern positive from negative sera. It should be noted that one
serum sample from the German blood bank resulted in a strong signal from the DOBV NP-
coupled microspheres.
Screening of human serum samples collected from Guinea in 2011–2012
using the MMIA
Serum samples collected from febrile human patients in Guinea in 2011 and 2012 (129 serum
samples) were screened for NP-specific IgG antibodies against CCHFV, RVFV, DOBV, EBOV
and MARV using the MMIA. The MMIA was performed in triplicate and the MFI results for
each antigen were analysed and compared with those obtained from the German blood bank
sample set (Fig 2). Here, the overall distribution patterns of log-transformed MFI values were
similar between the two serum sample sets. Samples were determined to be positive or negative
for each viral NP based on the conservative negative/positive threshold (cutoff) value deter-
mined by using the 99th percentile of the German blood bank samples. The total number of
positive and negative serum samples for each viral NP in both populations (German blood
bank and Guinea) are summarised and compared in Table 2.
A statistically significant difference between the number of positive serum samples in the
sample set from Guinea and the German blood bank was only observed when comparing
PLOS NEGLECTED TROPICAL DISEASES Multiplex immunoassay development to detect antibodies against highly pathogenic viruses
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008699 October 23, 2020 10 / 23
Fig 2. Histograms displaying the results of the MMIA for each viral NP. The x-axis displays the average MFI value for each serum sample tested in triplicate and the
y-axis displays the number of serum samples that resulted in each MFI value. The serum panel from the (A) German blood bank and (B) from Guinea are shown
individually. A conservative cutoff value is indicated by a vertical line on each plot, and was chosen based on the 99th percentile for serum samples in the German blood
bank panel. This is a population based cut-off and assumes that 99% of serum samples in the German blood bank are negative for the indicated virus. Samples were
assigned a positive or negative status based on this cutoff, and in all cases, negative serum samples are shown in grey and positive serum samples are shown in red.
https://doi.org/10.1371/journal.pntd.0008699.g002
Table 2. Comparison of the number of serum samples that tested positive and negative against each viral NP in the German blood bank and Guinean serum sample
sets. The median MFI readings from three technical replicates per sample were analysed in R, and a positive or negative status was assigned to each serum sample. Positiv-
ity or negativity was based on a cutoff MFI value that was determined for each viral NP based on the 99th percentile for MFI values in the German blood bank sample set.
Statistically significant differences in seroprevalence rates between the two sample sets and odds ratios were calculated using Fisher’s exact test.
Group Percentage Frequency† Cutoff Fisher’s exact test
Antigen Serostatus German Blood donor Guinea panel German Blood donor Guinea panel MFI P-value Odds ratio 95% CI
Bacterial lysate Negative 98.9 98.5 87 127 >0.9999 n.a.
Positive 1.1 1.6 1 2 896.4
CCHFV Negative 99.6 99.0 87 128 >0.9999 n.a.
Positive 0.4 1.0 0 1 5112.0
DOBV Negative 98.9 97.7 87 126 0.65 n.a.
Positive 1.1 2.3 1 3 7389.1
EBOV Negative 98.9 91.5 87 118 0.03 8.11 1.4 to 88,5
Positive 1.1 8.5 1 11 1866.5
MARV Negative 98.9 81.4 87 105 <0.0001 11.33 2.3 to 64.1
Positive 1.1 18.6 1 24 1689.7
RVFV Negative 98.9 94.1 87 121 0.09 n.a.
Positive 1.1 5.9 1 8 1433.0
† Only complete cases (all three replicates either positive or negative) were analysed
https://doi.org/10.1371/journal.pntd.0008699.t002
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reactivity against EBOV NP and MARV NP coupled microspheres (Table 2). In both cases, a
statistically significantly larger number of samples reacted positively against EBOV NP and
MARV NP in the serum set from Guinea compared to the serum set from the German blood
bank. Indeed, this analysis revealed that 18.6% of the serum samples within the Guinean
sample set were potentially positive for MARV NP antibodies and 8.5% were potentially pos-
itive for EBOV NP antibodies (Table 2). However, false positive readings, cross reactivity or
higher background readings for individual serum samples also cannot be ruled out at this
stage. In addition, several serum samples also reacted positively in the MMIA against other
viral NPs in the sample set from Guinea, especially against RVFV NP coupled microspheres
(Table 2). However, the overall reactivity for most sera was lower (below 10,000 MFI) as
compared to the infected non-human primates or human samples with known infections
status (Fig 1), most likely indicating an absence of recent contact with the highly pathogenic
viruses tested.
Comparison of the MMIA with commercial or in-house immunoassays
In order to confirm the results of the MMIA, positive serum samples from the sample set used
for assay validation, the German Blood bank donors and the Guinean sample sets were tested
using the corresponding commercially available immunoassay, or in the case of EBOV and
MARV, in-house ELISA. The commercial immunoassays used were as follows: CCHFV (NP-
based ELISA from VectorBest), RVFV (IIFT using RVFV infected cells from EUROIMMUN)
and DOBV (IIFT using DOBV infected cells from EUROIMMUN). Here, all highly positive
samples from the MMIA validation sample set (Fig 1) were confirmed as positive by the com-
mercial assays for their respective viral NPs (Table 1). In addition, two of the serum samples
that were part of the CCHFV validation panel that had high MFI readings for the RVFV NP-
coupled microspheres (12,786 and 20,233), also tested positive in the RVFV IIFT (titers of
1:400 and 1:1600 respectively). The serum sample from the German blood bank that had a
high MFI reading from the DOBV NP-coupled microspheres (9916) also tested positive in the
DOBV IIFT (titre of 1:800) thus confirming the accuracy of the MMIA. Two of the possible
RVFV positive samples in the Guinean sample set (MFI values 28,876 and 10,751), were tested
using the commercial RVFV IIFT, however only one (MFI 28,876) was confirmed positive
(titer of 1:1,600). This might be due to the increased sensitivity of the MMIA in comparison to
the IIFT. Probably for the same reason, three samples from Guinea that showed a relatively
strong signal from the DOBV NP coupled microspheres tested negative by IIFT. Another rea-
son could be differences in the antigens used in these assays (the antigens in the IIFT are
derived from DOBV-infected cells, whereas the antigen in the MMIA is recombinant DOBV
NP) and virus strains circulating in Guinea. A single sample from the Guinean sample set had
MFI readings >10,000 for CCHFV NP-coupled microspheres, and this sample also had a posi-
tive result when tested by the commercial CCHFV ELISA. It should be noted that ELISAs are
generally more sensitive than IIFTs.
Further analysis using more samples from the Guinean sample set together with the valida-
tion sample set revealed a positive correlation between the CCHFV ELISA and MMIA results
(Fig 3C). In the case of EBOV and MARV, commercial immunoassays were not available,
therefore in-house ELISAs were developed using recombinant EBOV NP and MARV NP.
Comparison of the results from the MMIA and in-house EBOV and MARV ELISAs revealed a
tight positive correlation between the two techniques (Fig 3A and 3B). Overall the agreement
between the ELISA/IIFT data and the MMIA data supports the use of the MMIA as a multiplex
screening tool for the detection of IgG antibodies against the NPs of CCHFV, RVFV, DOBV,
EBOV and MARV.
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Adaptation of the MMIA to analyse bat serum samples for antibodies
targeting EBOV and MARV
The MMIA was adapted to detect specific antibodies targeting EBOV NP and MARV NP from
bat serum samples by using a mixture of biotinylated protein A and protein G in place of the
biotinylated anti-human IgG secondary antibody. The sera analysed included sera taken pre-
inoculation, as well as sera taken 24 days after the inoculation of Mops condylurus micro bats
with either EBOV- or MARV-VLPs. Pre- and post-inoculation sera were analysed from 7 bats
inoculated with EBOV-VLPs and 8 bats inoculated with MARV-VLPs. When analysed by
MMIA the sera taken from bats 24 days after inoculation with EBOV- or MARV-VLPs showed
high MFI signals (MFI values between 2000–15,000) from their corresponding NP-coupled
microsphere regions, in contrast to MFI signals corresponding to background levels (MFI
values< 500) from the other 3 viral NP-coupled microsphere regions and from the pre-inocu-
lation bat sera (Fig 4). Only a single bat inoculated with MARV-VLPs failed to seroconvert.
These data demonstrate that this MMIA could be effectively adapted to detect NP-specific
EBOV and MARV IgG antibodies from bat sera, and, thus, underscores the versatility of this
assay.
Discussion
Monitoring of highly pathogenic viruses in human and wildlife populations is critical to enable
the effective assessment of the risk of spill-over human infectious disease outbreaks, as well as
epizootics. Furthermore, knowledge of circulating viruses in certain areas aids differential
diagnosis decisions of local healthcare providers for febrile patients. In this study, we describe
the development of a broadly reactive MMIA which detects IgG antibodies targeting the NPs
of CCHFV, DOBV, RVFV, EBOV and MARV and that could be used as a screening tool in
seroprevalence studies to assess the prevalence of antibodies against these viruses in certain
human and animal populations. By targeting IgG instead of IgM antibodies our MMIA is
designed to detect evidence of past infection with these viruses, not recent infection. IgG anti-
bodies can still circulate in serum for years after infection with a specific virus, thereby increas-
ing their chances of being detected, whereas IgM antibodies only circulate for a few months
Fig 3. Correlation between MMIA results and commercially available or in-house ELISAs for EBOV (A), MARV (B) and CCHFV (C). For both the MMIA and the
ELISAs results were obtained from 3 technical replicates for each sample and the average MFI value for each NP (EBOV, MARV or CCHFV) was then plotted against the
average absorbance values obtained from the same sample in the corresponding ELISA. In (A) and (B) all serum samples from the Guinea panel and the validation panel
were tested by in-house EBOV or MARV ELISAs, in (C) a subset of samples from the Guinea panel and validation panel were tested by commercial CCHFV IgG ELISA.
https://doi.org/10.1371/journal.pntd.0008699.g003
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post-infection, reducing the window of opportunity for detection. Therefore when surveilling
a novel cohort of humans or animals, an IgG based assay such as our MMIA can be used to
assess whether these viruses have previously circulated in a certain region, then further studies
of seropositive populations could include specific IgM detection assays to look for evidence of
more recent infections.
MMIAs have several advantages over ELISA and IIFT as they enable the simultaneous
detection of antibodies against multiple target antigens in a single assay, thereby conserving
serum samples, reagents and time [44,52]. In addition MMIAs have been shown to be more
sensitive and more cost effective than ELISAs [24,53,54]. However, the specific equipment
required to perform the MMIA and the initial associated start-up cost may present a barrier to
starting to work with these assays, and the higher sensitivity of the MMIAs compared to other
immunoassays can present significant challenges when developing novel assays and defining a
positive/negative cutoff and evaluating low positive samples. The lack of a standard, uniform
Fig 4. Analysis by MMIA of serum samples taken pre- and post-inoculation with EBOV- and MARV-VLPs from Mops condylurus micro bats. Serum samples
were taken from micro bats 24 days after inoculation with EBOV VLPs and MARV VLPs, and their reactivity to EBOV NP and MARV NP coupled microspheres was
compared to sera taken pre-inoculation. The MMIA was adapted to detect bat antibodies by exchanging the SAPE-conjugated anti-human secondary antibody with
SAPE-conjugated protein A and protein G. MFI readings for the same negative and EBOV-NP and MARV-NP positive NHP sera used as controls in all MMIAs are
shown in the first 2 columns.
https://doi.org/10.1371/journal.pntd.0008699.g004
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immunoassay to confirm the results of novel MMIAs further complicates their evaluation and
the designation of a cutoff value. For example, in this study both ELISAs and IIFTs (which are
known to have different sensitivities), commercial as well as those designed in-house, were
used to compare and confirm the results of the MMIA, as there was not one standard format
of commercial immunoassay available. This made the interpretation of the results more chal-
lenging than if, for example, ELISAs of comparative sensitivities existed for the detection of
IgG antibodies against each virus. There are several different statistical methods that can be
employed to define a cutoff value in novel MMIAs, but in the absence of definitive knowledge
of previous infection, it may not be possible to satisfactorily resolve individual samples with
MFI values very close to the cutoff. MMIAs of various different formats have been developed
to detect antibodies against numerous viral pathogens including multiple arboviruses [55,56]
and highly pathogenic viruses such as EBOV, Lassa virus, RVFV, CCHFV, and Hendra and
Nipah viruses [53,54,57,58]. An EBOV and LASV MMIA developed using both native antigen
from infected cells and recombinant antigen from a transfected human cell line (glycoprotein
complex (GPC) and nucleocapsid protein (NP) from LASV and glycoprotein (GP) and viral
matrix protein 40 (VP40) from EBOV) was shown to be 5 and 25 times more sensitive in
detecting IgM antibodies against LASV and EBOV, respectively, compared to the equivalent
ELISAs [54]. MMIAs which simultaneously detect antibodies against multiple recombinantly
expressed viral proteins of either RVFV or EBOV [53,58] have been developed. MMIAs such
as these not only provide greater certainty of a true positive result though the detection of anti-
bodies against multiple antigens of the same virus, but also enable the possibility of differentia-
tion between vaccinated and infected individuals in a single assay [59,60].
We chose to use the recombinant, bacterially expressed NPs of CCHFV, DOBV, RVFV,
EBOV and MARV as the viral antigen to couple to microspheres. The NPs of these viruses
have previously been shown to be highly immunogenic, and are often conserved between viral
species of the same genus [61,62] enabling the detection of antibodies targeting a broad range
of virus species in a single assay. Indeed, the successful detection of anti-EBOV NP antibodies
generated as a response to infection by different ebolaviruses, EBOV (Mayinga and Makona)
and RESTV in our MMIA, highlights the broadly reactive nature of EBOV NP and validates
our choice of NP as the MMIA antigen for this reason. Other viral proteins were also consid-
ered for use as the ‘bait’ antigen, for example the viral glycoproteins and non-structural pro-
teins (NS or virion proteins). However, these proteins have been shown to be less
immunogenic than NP or less broadly reactive than NP in previous studies [58,63,64] and,
therefore, were not chosen.
The use of recombinant bacterially expressed NPs as the antigen in the MMIA negates the
necessity for BSL-4 facilities to grow these highly pathogenic viruses to use as ‘bait’. However,
due to the bacterial expression of the NPs, high background MFI signals were detected against
most viral antigen-coupled microsphere regions when the MMIA was tested using human
control sera. These signals presumably arose as a result of the presence of contaminating bacte-
rial proteins co-purified with the viral NPs that were co-coupled to the microspheres, reacting
with anti-E.coli antibodies present in human sera. This high background was effectively elimi-
nated by the pre-incubation of each serum sample with assay buffer containing 5% E.coli
lysate. It is thought that during this incubation, anti-E.coli antibodies present in the serum
bound to their target proteins, thus removing them from the pool of available antibodies that
could bind to the bacterial proteins coupled to the microspheres during the assay. This has pre-
viously been shown to be an effective technique to reduce or remove background signals from
MMIAs [65]. In addition, one microsphere region was covalently coupled to E.coli cell lysate
and acted as a control during the assays–any serum samples that had MFI readings above
background levels to this microsphere region would be discounted from further analysis.
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Following assay optimisation, stringent assay conditions as well as stringent positive/nega-
tive cutoff values were chosen in order to decrease the chance of false positive signals. Given
the highly sensitive nature of MMIAs in comparison to ELISAs [54] and IIFTs, it was thought
that low positive MFI signals might not be able to be verified by an alternative serological
assay, therefore, stringent assay conditions were chosen to reduce the likelihood of this situa-
tion occurring. Indeed, in our MMIA the majority of serum samples that resulted in a very
high MFI value (> 20,000) for a specific viral antigen were confirmed as positive using either
the corresponding ELISA or IIFT. However, some samples that had a clearly higher than back-
ground MFI value (between 4000 and 12,000 in the case of RVFV NP-coupled microspheres,
for example), sometimes did not test positive by an alternative immunoassay, presumably due
to the higher sensitivity of the MMIA. Samples with a low positive MFI signal such as these
must be considered on an individual basis, as they could also possibly be false positives, arising
for example, due to incorrect storage of serum samples and sample degradation. Titration of
such samples and re-testing in the MMIA may provide more clarity, as often false positive
samples will test negative at a lower dilution than true positive samples. However, it should
also be noted that some very low positive signals may not be detected in our MMIA due to the
stringent assay conditions that were chosen.
A set of 129 serum samples collected in Guinea in 2011 and 2012 were assayed in the
MMIA to further test the MMIA and to screen this population for IgG antibodies against
CCHFV, RVFV, DOBV, EBOV and MARV NPs. Any serum that resulted in high MFI values
was also tested using the commercially available immunoassay, or in the case of EBOV and
MARV, by in-house ELISAs. Overall, there was a positive correlation between the MMIA and
the alternative ELISA or IIFT, indicating the MMIA functioned well as an IgG antibody
screening tool. However, the commercial immunoassays that were used also have their limita-
tions, and the samples that tested positive using the in-house and commercial ELISAs were
not titrated. Therefore, further development and validation of this MMIA could include addi-
tional testing of positive samples using different assays by a different laboratory, and titration
and re-testing in the ELISA and MMIA. This might provide more of an indication of whether
these sera were reacting specifically to the viral NPs, as well as potentially providing more
information about the relative sensitivity of the 2 assays.
However, there were 3 serum samples from the Guinean sample set that tested positive for
DOBV NP by MMIA but were negative in the corresponding IIFT. These could be false posi-
tives, or the results may be due to the fact that the slides of the DOBV confirmatory IIFT
(EUROIMMUN) are made using DOBV-infected cells whilst the MMIA uses the more
broadly reactive DOBV NP as the antigen. The presence of DOBV itself has yet to be docu-
mented on the African continent, however other novel Hantaviruses have been isolated and
sera were shown to cross react with DOBV [13,16,66]. Therefore, circulating hantavirus strains
in Guinea may elicit an antibody reaction that can be detected by the more cross-reactive NP-
coupled to microspheres, but these antibodies do not result in a detectable reaction when
assayed using DOBV-infected cells.
There were serum samples that were reactive against more than one viral antigen in the
MMIA, corresponding to human sera double or triple positive for EBOV, MARV, RVFV,
DOBV or CCHFV NPs. It is conceivable that a sample could test positive against more than
one of these viral antigens (indeed, 2 serum samples from the CCHFV validation panel were
independently confirmed by commercial IIFT to also potentially be positive for RVFV IgG)
due to the individual having been infected with more than one of these viruses. However it is
also possible that some serum samples are more non-specifically reactive than others, and may
produce false positive results. Another MMIA could be developed by coupling other antigens
from these viruses to microspheres (glycoproteins or matrix proteins for example) in order to
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increase assay specificity, after the initial screen had been completed with our broadly reactive
NP based MMIA. Serum samples have, for example, tested positive against the NP of EBOV,
but tested negative against the EBOV glycoprotein [67]. It is speculated that sera such as this
could be reacting against the broadly reactive NP of distantly related filoviruses. Interestingly,
when the MMIA results of the sample set from Guinea were compared with those of the Ger-
man blood bank, only the number of positive reactions against the EBOV NP and MARV NP
were found to be increased to a statistically significant degree in the sample set from Guinea.
This implies the possible circulation of filoviruses in this human population before 2013 (sam-
ples were collected in 2011 and 2012). However, assays to more clearly determine specificity to
EBOV and MARV (for example serological assays using other EBOV and MARV antigens,
such as the glycoprotein or non structural proteins as bait, or titration of the serum samples)
should be performed before any definitive interpretation of these results are made. These data
are however in accordance with previous serological surveys of human samples for antibodies
against EBOV and MARV: high seropositive rates have been reported for EBOV and MARV
in human populations in the Central African Republic, the Republic of Congo and the Demo-
cratic Republic of the Congo [68–70]. Indeed, an overall seroprevalence rate of 15.3% for anti-
bodies against EBOV has previously been reported in Gabon [71]). Also in agreement with
our findings, a recent study using a MMIA specific for EBOV documented EBOV IgG anti-
bodies in human serum samples collected in Guinea in 2012, although the first recorded case
of EBOV in Guinea was not reported until the following year (December 2013) [67]. There is
an increasing body of evidence that EBOV and MARV are capable of causing asymptomatic or
mild infections, which may account for the detection of EBOV- and MARV-specific antibodies
in the human population in the absence of a history of haemorrhagic symptoms or an outbreak
of haemorrhagic disease [72–74]. Indeed recent studies have documented the presence of anti-
EBOV antibodies in populations with no history of EBOV outbreaks in the Democratic
Republic of the Congo (overall 11% positivity rate of IgG antibodies to Zaire Ebola virus) and
Southwestern Uganda [75,76]. Alternatively, it is also possible that these antibody prevalence
rates may be accounted for by milder, as-yet-undocumented strains/species of filoviruses that
may be circulating undetected in human populations. In support of this theory, genomic
sequences of 2 new filoviruses (Bombali virus and Měnglà virus) have recently been discov-
ered in bats, although their ability to infected humans has yet to be determined [18,77]. Inter-
estingly, serum from fruit bats in Southeast Asia was found to be reactive against the
glycoprotein of various filoviruses when tested by MMIA [78], suggesting the presence of filo-
viruses antigenically related to Bundibugyo, Ebola, and Sudan virus in Southeast Asia, however
the causative virus has yet to be identified. When human serum taken from individuals
involved in hunting these species of bats in Northeast India were tested using the same MMIA,
several human serum samples also reacted positively against these filovirus glycoproteins, as
did serum samples taken from the bats they hunted [79]. This implies zoonotic spillover events
had occurred, in the absence of human disease outbreaks being reported. These data support
the possibility that filoviruses related to EBOV and MARV may circulate un-noticed in human
populations.
Indeed, our MMIA was also adapted to detect antibodies from bats, Mops condylurus, after
inoculation with EBOV- and MARV-VLPs. High MFI readings were obtained 24 days post
inoculation from EBOV NP and MARV NP-coupled microspheres, confirming an antibody
response from the micro bats, and demonstrating the adaptability of the MMIA. In fact, this
assay could easily be adapted to screen animal sera from other species for the presence of anti-
bodies against these viruses, to confirm their circulation in defined animal populations, such
as livestock. CCHFV, RVFV, DOBV, EBOV and MARV are all zoonotic pathogens that are
transmitted from animals or insect vectors to humans, and knowledge regarding their
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presence and circulation in animal populations could be invaluable to help identify at-risk
human populations that live in close proximity to these animals, as well as helping to protect
the animals themselves. Identification of livestock populations with exposure to CCHFV and
RVFV, for example, would imply these viruses are circulating in the region these livestock are
kept, and indicate vector control measures should be strictly adhered to or implemented, to
reduce the risk of human exposure to these viruses. In case of evidence of CCHFV circulation
in livestock, slaughter house workers should take precautions to avoid virus exposure. In addi-
tion the MMIA could be used to assay wild animal populations to identify zoonotic virus reser-
voirs. The MMIA would enable the high throughput detection of antibodies against several
viruses simultaneously using a very small sample volume, which would be advantageous over
other methods when, for example, surveilling small mammals or birds where humane extrac-
tion of large quantities of serum may not be feasible.
Supporting information
S1 Fig. Coomassie stained gels of purified recombinant NPs of EBOV, MARV, CCHFV,
RVFV and DOBV. ~6 ug viral NP was loaded per lane of a polyacrylamide SDS gel (with the
exception of DOBV NP). Following electrophoresis at 200 V for 30 minutes, gels were stained
by overnight incubation at room temperature in Coomassie stain. After de-staining, gel images
of were captured using a ChemiDoc imager. The dominant band in each gel image corre-
sponds to the correct molecular weight for the indicated viral NPs.
(TIF)
S2 Fig. MMIA optimisation. The MMIA was optimised by varying the amount of each puri-
fied NP that was bound to 1 x 106 microspheres in order to achieve the maximum MFI signal
intensity, whilst maintaining the lowest possible background MFI signal. (A) depicts the opti-
misation of the amount of CCHFV NP coupled to microspheres using 5 μg, 20 μg and 50 μg of
CCHFV NP per 1 x 106 microspheres. CCHFV NP binding was detected using dilutions of
hyper-immune sheep sera ranging from 1:12,800 to 1:640,000 diluted in assay buffer. (B)
depicts the optimisation of the amount of RVFV NP coupled to microspheres using 7 μg,
35 μg and 70 μg of RVFV NP per 1 x 106 microspheres. RVFV NP binding was detected using
dilutions of hyper-immune mouse sera ranging from 1:10,000 to 1:640,000 diluted in assay
buffer. The MMIA was also optimised in order to reduce the MFI signals generated by anti-
bodies in serum binding to bacterial proteins present in the purified NP preparations, by pre-
incubating the serum in assay buffer containing 5% E.coli lysate for 30 minutes. In (C) the MFI
signals arising from the protein coated and unbound microspheres after a 1 hr incubation with
human serum diluted 1:100, 1:200 or 1:400 in assay buffer is shown. This is in contrast to (D)
where the MFI signals arising from the same human serum samples are shown, however in
(D) the serum dilutions were first pre-incubated in assay buffer containing 5% E.coli lysate,
prior to the 1 hr incubation with protein coated and unbound microspheres. The horizontal
dotted line in (C) and (D) represents an MFI signal of 300 units.
(TIF)
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